Skip to main content
Premium Trial:

Request an Annual Quote

Nicolas Barthelemy, Carlos Paya

Fluidigm said this week that it has appointed Nicolas Barthelemy and Carlos Paya to its board of directors. Barthelemy most recently served as president and CEO of molecular diagnostics firm Biotheranostics. He previously served as president of global commercial operations at Life Technologies and has also led the firm's cell systems division. He also serves on the board of directors of Repligen. Paya is president, CEO, and director of immunotherapy firm Immune Design. He formerly served as president of pharmaceutical firm Elan, and was VP of Lilly Research Laboratories.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.